Xue Y, et al. – The efficacy and safety of sofosbuvir and daclatasvir regimens were evaluated for kidney transplantation (KT) patients with hepatitis C virus (HCV) infection. For treatment of KT recipients with HCV infection, sofosbuvir and daclatasvir were highly efficient and safe. As per the outcomes, patients tolerated the medications well. There were no serious adverse events (AEs). For validating these results, larger prospective cohort studies were needed.